Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026)
Lb Pharmaceuticals' (LBRX) quarterly Income from Continuing Operations came in at 19054000.0 in Q1 2026, down 259.1% year-on-year from 11975897.18 in Q1 2025, and down 66.09% quarter-over-quarter from 11472000.0 in Q4 2025.
Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Lb Pharmaceuticals' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 19054000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 259.1% year-over-year to 19054000.0 in Q1 2026; TTM through Mar 2026 was 39388000.0, a N/A change from a year earlier, with the FY2025 full-year figure at 25205000.0, up 60.06% from the prior year.
- Income from Continuing Operations slipped to 19054000.0 in Q1 2026 per LBRX's latest filing, from 11472000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3556000.0 in Q3 2025 and bottomed at 19054000.0 in Q1 2026.
- The 3-year median for Income from Continuing Operations is 8389000.0 (2025), against an average of 9773333.33.
- Across the five-year window, Income from Continuing Operations soared 74.92% in 2025 and slumped 259.1% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 5071000.0 in 2024, then slumped by 126.23% to 11472000.0 in 2025, then sank by 66.09% to 19054000.0 in 2026.
- Per Business Quant, the three latest LBRX Income from Continuing Operations figures stand at 19054000.0 (Q1 2026), 11472000.0 (Q4 2025), and 3556000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Lb Pharmaceuticals | 977.73 Mn | 977.73 Mn | - | -19.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -11.47 Mn |
| Sep 30, 2025 | -3.56 Mn |
| Mar 31, 2025 | -5.31 Mn |
| Dec 31, 2024 | -5.07 Mn |
| Sep 30, 2024 | -14.18 Mn |